Skip to main content
Reported segment mix · SEC DERA dimensional facts

Zoetis Inc. ZTS revenue by segment, product and geography

In its fiscal year ending 2025-12-31, Zoetis Inc. reported revenue across 20 products and services; the largest, Total Productsand Services, was $9.35B (+1.9% against the prior period in the same filing).

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K filed 2026-02-12prior period 2024-12-31 from the same filingView filing
By product or service
Revenue
  • Total Productsand Services$9.35B
    share n/a
    +1.9% yoy
  • Companion Animal$6.59B
    share n/a
    +4.9% yoy
  • Horses$6.28B
    share n/a
    +4.8% yoy
  • Livestock$2.76B
    share n/a
    -4.6% yoy
  • Parasiticides$2.34B
    share n/a
    +8.7% yoy
  • Vaccines$1.96B
    share n/a
    +7.2% yoy
  • Dermatology$1.75B
    share n/a
    +6.0% yoy
  • Cattle$1.49B
    share n/a
    -2.5% yoy
  • +12 more members in the filing

member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.

By geography
Revenue
  • Total Geographical Area$9.35B
    share n/a
    +1.9% yoy
  • United States$5.1B
    share n/a
    +0.5% yoy
  • Other Emerging Markets$913M
    share n/a
    +5.5% yoy
  • Other Developed Markets$641M
    share n/a
    +13.7% yoy
  • Brazil$393M
    share n/a
    -5.1% yoy
  • Australia$329M
    share n/a
    +3.1% yoy
  • United Kingdom$325M
    share n/a
    +3.5% yoy
  • Canada$290M
    share n/a
    +4.7% yoy
  • +8 more members in the filing

member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.

Latest quarter
Quarter ending 2026-03-3110-Q filed 2026-05-07prior period 2025-03-31 from the same filingView filing
  • Total Productsand Services$2.24B
    share n/a
    +3.3% yoy
  • Companion Animal$1.52B
    share n/a
    -1.4% yoy
  • Dogs And Cats$1.44B
    share n/a
    -2.3% yoy
  • Livestock$720M
    share n/a
    +14.8% yoy
  • Parasiticides$586M
    share n/a
    +2.4% yoy
  • Vaccines$519M
    share n/a
    +18.2% yoy
  • +13 more members in the filing

Change is against the same quarter a year earlier, as reported in the same 10-Q.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

About these figures

Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.

Descriptive and educational; not investment advice. Methodology and data lineage.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.

Zoetis Inc. (ZTS) revenue by segment, product and geography FY2025 | TrendNalysis